High pathological complete remission rates with paclitaxel and carboplatin ± trastuzumab (TC±H) following dose dense doxorubicin and cyclophosphamide (AC) supported by GM-CSF in breast cancer-a phase I study.

被引：0
|
作者：
Mehta, RS [1 ]
Schubbert, T [1 ]
Hsiang, D [1 ]
Butler, J [1 ]
Baick, C [1 ]
Su, MY [1 ]
机构：
[1] Univ Calif Irvine, Orange, CA 92668 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 33 条
  • [1] Phase II study of neoadjuvant biweekly doxorubicin and cyclophasphamide (AC) with GM-CSF followed by weekly paclitaxel, carboplatin ± trastuzumab (TC ± H) in the treatment of breast cancer (BC).
    Mehta, RS
    Shubbert, T
    Hsiang, D
    Kong, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 84S - 84S
  • [2] Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF in the treatment of patients with advanced ovarian cancer (FIGO III and IV) -: a phase I study
    Sieger, D
    D'Addario, G
    Lorenz, U
    Bacchi, M
    Thürlimann, B
    ONKOLOGIE, 1999, 22 (06): : 502 - 506
  • [3] In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) → weekly carboplatin and albumin-bound paclitaxel (nab-TC)/trastuzumab (H)/bevacizumab (B) in large and inflammatory breast cancer (BC): A phase II study
    Bernstein, J. A.
    Mehta, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -> weekly carboplatin and albumin-bound paclitaxel (nab-TC) plus trastuzumab (H) or bevacizumab (B) in patients with large and inflammatory breast cancer (BC): A phase II study
    Mehta, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase II study of neoadjuvant weekly carboplatin/paclitaxel followed by dose-dense doxorubicin/cyclophosphamide (DD AC)in patients with triple negative breast cancer (TNBC): Wisconsin oncology network (WON) study
    Cheng, Yee Chung
    O'Regan, Ruth
    Chaudhary, Lubna N.
    Kamaraju, Sailaja
    Einhorn, Harvey
    Sampene, Emmanuel
    Pigsley, Marialane
    Burkard, Mark E.
    Chitambar, Christopher R.
    Wisinski, Kari B.
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Pathologic complete response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in patients (pts) with doxorubicin/cyclophosphamide-resistant (AC-Res) and AC-sensitive (AC-S) large and inflammatory breast cancer
    Mehta, R. S.
    Schubbert, T.
    Kong, K.
    Hsiang, D.
    Butler, J.
    Baick, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
    Slamon, D.
    Eiermann, W.
    Robert, N.
    Pienkowski, T.
    Martin, M.
    Rolski, J.
    Chan, A.
    Mackey, J.
    Liu, M.
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T.
    Olsen, S.
    Buyse, M.
    Kiskartalyi, T.
    Landreau, V
    Wilson, V
    Press, M.
    Crown, J.
    CANCER RESEARCH, 2009, 69 (24) : 500S - 500S
  • [8] Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC ± H) based on HER2 status in large and inflammatory breast cancer (BC).
    Mehta, R. S.
    Schubbert, T.
    Jackson, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A phase I-II study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC).
    Andreopoulou, Eleni
    Vigoda, Ivette Sara
    Valero, Vicente
    Hershman, Dawn L.
    Raptis, George
    Vahdat, Linda T.
    Han, Hyo S.
    Wright, John Joseph
    Pellegrino, Christine M.
    Alvarez, Ricardo H.
    Fehn, Karen
    Fineberg, Susan
    Sparano, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA).
    Dang, C.
    Smith, K.
    Fornier, M.
    Sugarman, S.
    Troso, T.
    Lake, D.
    D'Andrea, G.
    Seidman, A.
    Sklarin, N.
    George, R.
    Dickler, M.
    Currie, V
    Gilewski, T.
    Moynahan, M. E.
    Drullinsky, P.
    Poznak, C.
    Robson, M.
    Wasserheit, C.
    Mills, N.
    Steingart, R.
    Norton, L.
    Hudis, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S114 - S115
1234